Friday, Bioanalytical Systems announced a collaboration with Data Sciences International (NYSEARCA:DSI) to conduct a pioneering study that combines Bioanalytical Systems' Culex-L automated sampling system with PhysioTel Digital, DSI's latest large animal telemetry technology. DSI is a biomedical research company with its focus on preclinical systems physiology and pharmacology.
In this groundbreaking study, BASi's Culex-L automated in vivo sampling system will simultaneously gather biological samples at pre-programmed intervals while DSI telemetry devices collect heart rate, blood pressure, and other cardiovascular data. The gathering of these various types of data formerly required two separate experiments and allowed only discontinuous data collection.
Combining Culex with telemetry will result in reductions in cost, number of test subjects, and subject test levels for the automated blood sampling and telemetry (ABST) system, as well delivery of better data. This will collectively lead to better decision making. The study will lay the groundwork for additional safety pharmacology studies to further complement BASi's CRO services expertise.
These efforts are in response to customer requests for additional and improved pharmacokinetic data, which is crucial for early decision-making in the drug discovery process. Joining DSI's telemetry with BASi's automation is a natural fit.
Bioanalytical Systems is a pharmaceutical development company engaged in providing contract research services and monitoring instruments to the world's premier drug development companies and medical research organizations. The company is focused on the development of innovative services and products that enhance efficiency and decrease the cost of taking a new drug to market.
For more information, visit BASinc.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net